

15 August 2024

Treatment of Haematology

MYELOPROLIFERATIVE DISEASES

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Fedratinib (Inrebic)	
1.2 Momelotinib (Omjjara)	
1.3 Ruxolitinib (Jakavi)	
1.4 Hydroxycarbamide	

Q2 How many patients were treated for the following myeloproliferative diseases in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Diagnosis with ICD10 codes	Number patients treated
2.1 Polycythaemia vera ICD10 codes = D45, D450, D45.0, D45X OR morphology code = 9950/3	
2.2 Myelofibrosis ICD10 codes = C944, C94.4 or D474, D47.4; OR morphology codes = 9931/3 or 9961/3	
2.3 Essential thrombocythemia ICD10 code = D473, D47.3 OR morphology code = 9962/3	
2.4 Myeloproliferative Disease, Chronic ICD10 code = D471, D47.1	

Q3. How many patients with Myelofibrosis (ICD10 codes = C944 or D474; OR morphology codes = 9931/3 or 9961/3) were treated with the following

15 August 2024

medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of medicine	Number patients treated
3.1 Fedratinib (Inrebic)	
3.2 Momelotinib (Omjjara)	
3.3 Ruxolitinib (Jakavi)	
3.4 Hydroxycarbamide	
3.5 Peginterferon Alfa-2a (Pegasys)	
3.6 Roppeginterferon Alfa-2b (Besremi)	
3.7 Epoetin alfa (Eprex, Binocrit)	
3.8 Epoetin beta (NeoRecormon, Mircera)	
3.9 Epoetin zeta (Retacrit)	
3.10 Darbepoetin (Aranesp)	
3.11 No active treatment	
3.12 Allogeneic stem cell transplant	

Q4. How many patients were treated with ruxolitinib (Jakavi) in combination with epoetin in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Please include all types of epoetin – epoetin alfa, epoetin beta, epoetin zeta, darbepoetin alfa

Name of medicine	Number patients treated
4.0 Ruxolitinib (Jakavi) + epoetin	

NON HODGKIN LYMPHOMA (NHL) AND CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

15 August 2024

Name of medicine	Number patients treated
5.1 Acalabrutinib (Calquence)	
5.2 Ibrutinib (Imbruvica)	
5.3 Pirtobrutinib (Jaypirca)	
5.4 Venetoclax (Venclyxto)	
5.5 Zanubrutinib (Brukinsa)	

Q6. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of medicine	Number patients treated
6.1 Acalabrutinib (Calquence)	
6.2 Ibrutinib (Imbruvica)	
6.3 Pirtobrutinib (Jaypirca)	
6.4 Venetoclax (Venclyxto)	
6.5 Zanubrutinib (Brukinsa)	

Q7. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of monotherapy or combination	Number patients treated
7.1 Ibrutinib + venetoclax	
7.2 Obinutuzumab + venetoclax	
7.3 Acalabrutinib monotherapy / maintenance	
7.4 Zanubrutinib monotherapy / maintenance	
7.5 Ibrutinib monotherapy / maintenance	
7.6 Venetoclax monotherapy	
7.7 Venetoclax + rituximab	

15 August 2024

MANTLE CELL LYMPHOMA

Q8. How many patients with Mantle Cell Lymphoma – ICD10 code = C831, C83.1 - were treated in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

	Number patients treated
8.0 Treated for Mantle Cell Lymphoma	

Q8.1 How many patients with Mantle Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of medicine	Number patients treated
8.1 MaxiCHOP + rituximab + high dose Cytarabine or NORDIC protocol	
8.2 Stem Cell Transplant	
8.3 Rituximab + bendamustine + cytarabine	
8.4 Rituximab + bendamustine	
8.5 Ibrutinib	
8.6 Rituximab + CHOP, Rituximab + CVP or rituximab + other chemo	
8.7 Acalabrutinib + rituximab + bendamustine	

We are unable to provide this information. We do not have electronic prescribing in haematology, retrieving this data would require a manual trawl of the notes of all patients with the listed diagnoses to identify their medications which would involve a significant number of hours. This would exceed the costs limit specified in the FOI act.

We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.